



Advanced Cancer Therapies 2027 Abstract Submission Guidelines and Requirements

KEY DATES

Abstract Submission Deadline: October 12, 2026, 11:59 PM (CST)

Abstract Administrative Corrections/Revisions Deadline: November 6, 2026

Abstract Withdrawal Deadline: November 6, 2026

Abstract Notifications Sent: Late November 2026

As you prepare your submission to the Meeting, please make note of the following details:

Submission Tracks and Categories

Authors must select one topic category that best fits the subject of their abstract. The Advanced Cancer Therapies Committee seeks abstracts in the following categories:

- Peritoneal Metastases
- HPB
- Applied Research
- Sarcoma/Melanoma
- Clinical Trials

Submission Requirements

- **Character Limit**

Abstracts must not exceed **2,300 characters**, including the title and body. Spaces are not counted toward the limit. Most special characters will transfer correctly when copying from a word processor. A character palette is available for additional symbol input.

- **Title Formatting**

Use **sentence case** (capitalize only the first word and proper nouns). Avoid periods, all caps, all lowercase, and formatting tags. Titles will be automatically formatted for print. **Product or brand names are not allowed**—use only generic names. Titles containing brand names will be disqualified.

- **Abstract Body**

The abstract must include the following clearly labeled sections:

- **Introduction:** 2–3 sentences outlining the study’s objectives.
- **Methods:** Brief description of the study design (e.g., retrospective chart review, prospective trial). Do not include detailed lab techniques or mention the institution.
- **Results:** This should comprise 50–66% of the abstract. Include key data necessary for evaluation. Abstracts stating “data will be presented” will be disqualified.
- **Conclusions:** 2–3 sentences summarizing the significance of the findings in relation to the objectives.

Please Note: All text will be formatted in plain text. Any use of bold, italics, or color will be converted to plain text.

- **Learning Objective**

Clearly state what participants will be able to do after engaging with your presentation.

- **Table or Image**

You may upload **one table or one image**. This does **not** count toward the character limit and can be edited or removed until the submission deadline of October 12, 2026, at 11:59 PM (CST).

- **Category**

Select the **one topic category** that best aligns with your abstract content.

- **Authors**

Provide a complete list of all authors in the intended order of appearance. For each author, include their full name, email address, credentials, and institutional affiliation. If a primary presenter is not specified, the submitting author will be designated as the presenter by default. **The author list is considered final after the October 12, 2026, submission deadline. Authors may not be added or removed thereafter; only corrections**

to author information and author order changes will be permitted through November 6, 2026.

- **Disclosure, Release and IRB Approvals**

The primary author and/or primary presenter must provide Presenter Release and IRB approval (if applicable).

If your abstract is accepted for an oral or video presentation, SSO requires the primary author and primary presenter to disclose financial relationships with any ineligible companies from the past 24 months and acknowledge any related support. All co-authors must agree with the content of the abstract to be considered for presentation. Refer to the [Conflict-of-Interest Policy](#) and follow the instructions provided in the submission process. Disclosure details will be included with acceptance letters.

- **Administrative Corrections/Revisions**

Revisions permitted until the abstract submission deadline of October 12, 2026:

- All abstract edits
- Author additions or removals

Limited administrative and minor editorial corrections permitted until November 6, 2026:

- spelling, grammar, or formatting corrections
- corrections to author names, degrees, or affiliations
- author order adjustments

The abstract review period begins on October 16, 2026. **No substantive scientific revisions, including changes to data, results, analyses, or conclusions, will be permitted after October 12, 2026.**

The author list submitted by October 12, 2026, is considered final. New authors may not be added, and authors may not be removed after the submission deadline.

Any administrative and minor editorial corrections must be submitted to advancedtherapies@surgonc.org by **November 6, 2026.**

- **Withdrawals**

Abstract withdrawal requests must be submitted to advancedtherapies@surgonc.org by **November 6, 2026.**

Withdrawals requested after November 6, 2026, **will not be permitted** except under extraordinary circumstances and at the discretion of SSO.

ACPMP Travel Awards

Through the generosity of ACPMP (Appendix Cancer Pseudomyxoma Peritonei Research Foundation), SSO awards **\$1,000** to the highest scoring abstracts in the content/research areas of appendix cancer, pseudomyxoma peritonei, peritoneal surface malignancies/peritoneal carcinomatosis, and/or HIPEC as may be applicable to appendiceal neoplasms.

Applicants will attest to specific criteria during submission. All abstracts will be blind-reviewed by the ACT Program Committee and recipients will be selected based on grade, abstract quality, and content relevance.

Eligibility Criteria:

- The abstract must be submitted by a **medical student, resident, fellow or early career physician. Residents and Fellows must be** currently enrolled in one of the following:
 - **ACGME accredited General Surgical residency**
 - **ACGME accredited Complex General Surgical Oncology Fellowship**
 - **SSO-ASBrS approved Breast Surgical Oncology Fellowship**
- Applicants must be **working with or sponsored by an SSO member**.
- SSO defines a Medical Student, Resident, Fellow, or Early Career Physician as follows:
 - Resident/Fellow: A Resident or Fellow of good standing at the time of abstract submission. If a submitter completes their residency or fellowship prior to the ACT meeting, the submitter still qualifies for award consideration.
 - Early Career: A physician who has completed their residency or fellowship within the last three (3) years.
 - Medical Student: A medical student (MD, DO) enrolled and in good standing at the time of abstract submission. If a submitter graduates from medical school prior to the ACT meeting, they still qualify for award consideration.

Additional Requirements:

- The paper must be presented by the **medical student, resident, fellow, or early career physician** at **ACT 2027**.
- Winners must attend ACT 2027 in person and acknowledge ACPMP in all poster and oral presentations during the event as a condition of the Travel Award.

APP Travel Grant

The Society of Surgical Oncology (SSO) is pleased to award up to four (4) travel grants of \$500 each to Advanced Practice Providers (APPs) whose abstracts receive the highest ratings among those accepted for presentation at the Advanced Cancer Therapies (ACT) Conference.

Abstracts will be reviewed and scored in their usual categories as part of the main abstract pool. Based on their scores, abstracts may be selected for inclusion in the main program or for presentation during the Quick Shot Poster Presentation session following the ACT 2027 APP Pre-Course.

Eligibility Criteria:

- The abstract must be submitted by an APP who is a current SSO member.
- The research must primarily reflect the work of the APP, although co-authors may be included.
- The presenting author must either be an SSO member or be sponsored by an SSO member.
 - Non-members must provide written verification of sponsorship from an active SSO member.

Additional Requirements:

- The selected abstract must be presented by the APP at ACT 2027.
- If the abstract presenter is not an SSO member, their sponsor must be registered and attend ACT 2027.
- Finalists will receive detailed instructions upon notification of selection.

SSO Copyright Policy for Abstract Submissions

By submitting an abstract to the Society of Surgical Oncology (SSO), you acknowledge and agree to the following:

- You affirm that the submitted abstract and any resulting presentation are your **original work**.
- If your abstract is accepted, you grant SSO the right to use all related materials for **educational and promotional purposes**. This may include, but is not limited to:
 - **Recording and distributing** your oral presentation
 - **Publishing** your abstract or excerpts in print and/or digital formats
 - **Selling recordings** of the presentation as part of SSO's educational resources
- You confirm that you **own or control all rights** to the abstract and presentation and have the legal authority to assign those rights.
- Upon acceptance, you agree to **assign to SSO all copyrights** in your abstract and presentation materials, in any medium.

If you have questions about this policy or your rights, please contact the SSO Meetings Team at advancedtherapies@surgonc.org.

Presentation/Publication Prior to the Advanced Cancer Therapies Meeting

Abstracts that have been previously presented or published, or that are scheduled for presentation or publication prior to the Advanced Cancer Therapies (ACT) 2027 Meeting, are eligible for submission and consideration.

Please note that if you plan to submit the same abstract to both the ACT Meeting and the SSO Annual Meeting, the SSO Annual Meeting has different eligibility requirements regarding prior presentation and publication. Certain prior presentations and publications may render an abstract ineligible for consideration at the SSO Annual Meeting. Authors are encouraged to review the [SSO Annual Meeting Abstract Submission Guidelines](#) before submitting.

If you have questions regarding abstract eligibility, please contact the SSO Meetings Team at advancedtherapies@surgonc.org.

Abstract Selection Process & Presentations

What happens after I submit my abstract?

Once the submission period closes, all abstracts undergo a **blind peer review** conducted by members of the Advanced Cancer Therapies Committee. The **Advanced Cancer Therapies Committee** is responsible for all final decisions regarding abstract acceptance, presentation format, and scheduling.

To ensure **unbiased, high-quality presentations** and compliance with CME accreditation standards, all reviewers, session planners, and invited faculty are required to **disclose relevant financial relationships** through the designated online system.

Abstract Acceptance Notification & Presentation Requirements

Submitters will receive email confirmations upon both the initiation and completion of their abstract submission.

If your abstract is **accepted for presentation at ACT 2027**, the presenting author will receive an official notification from the Advanced Cancer Therapies Committee by **late November 2026**.

Important Guidelines for Accepted Abstracts:

- **Reminder: Abstracts may not be withdrawn after the deadline of November 6.**
- If the presenting author is unable to attend in person, a replacement presenter may be designated.
 - Newly designated presenters must submit financial disclosure information to the SSO.

Meeting Attendance Requirement:

- Prior to submission, ensure that the **presenting author or a co-author will be available to attend the meeting** and present the work.
- All presenters of accepted abstracts are required to:
 - **Register for the meeting**
 - Cover their own **travel and registration expenses**

If you have any questions, please contact the SSO Meetings Team at advancedtherapies@surgonc.org.

Accepted Abstracts and SSO Journals

Can I submit my accepted abstract to *Annals of Surgical Oncology* or *Surgical Oncology Insight*?

Yes. SSO encourages all presenters to publish their research in its official journals:

- *Annals of Surgical Oncology (ASO)*
- *Surgical Oncology Insight (SOI)*

SSO leadership strongly supports the dissemination of Advanced Cancer Therapies research through these publications. Details and submission instructions will be provided for accepted presenters.

Further Questions?

If you have any questions about the ACT 2027 Abstract Submission process, please refer to the [ACT 2027 Abstract Information](#).

For additional assistance, please contact the SSO:

 **Phone:** 847-427-1400 (Monday–Friday, during business hours)

 **Email:** advancedtherapies@surgonc.org

We're here to help!